3E10 Antibody Nucleic Acid Delivery Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face limitations such as complexity in production, limited packaging capacity, and unfavorable immunological features, particularly in vivo, for the delivery of nucleic acids, necessitating an improved transfection technology.
Innovation Solution
The use of 3E10 monoclonal antibodies or their fragments, non-covalently linked with nucleic acid cargo, to facilitate the intracellular delivery of nucleic acids, including DNA, RNA, and modified nucleic acids, through a cell-penetrating mechanism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for nucleic acid delivery, then delivery efficiency is improved, but production complexity and immunological risks increase
Solution Approach 1:
The patent replaces complex viral vectors with simple, non-viral lipid-based delivery systems that are easier to produce and do not carry immunological risks. The lipid compositions are designed to be transient and disposable, forming temporary complexes with nucleic acids for delivery without requiring complex viral production infrastructure.
Solution Approach 2:
The patent modifies the physical and chemical parameters of lipid compositions to optimize nucleic acid delivery. By adjusting lipid ratios, chain lengths, and headgroup compositions, the system achieves efficient delivery without the complexity of viral vector production while maintaining or improving delivery efficacy.
2Productivity
If viral vectors are used for nucleic acid delivery, then delivery efficiency is improved, but immunological risks increase
Solution Approach 1:
The patent employs non-viral lipid-based delivery systems that avoid the immunological pitfalls of viral vectors. These lipid compositions are biocompatible, transient, and do not trigger strong immune responses, providing a safer alternative while maintaining delivery efficiency through optimized molecular design.
Solution Approach 2:
The patent uses lipid molecules as intermediary carriers that mediate nucleic acid delivery without the immunogenicity of viral vectors. These lipids form temporary complexes with nucleic acids, facilitate cellular uptake, and then degrade into benign components, serving as a safe intermediary between the therapeutic nucleic acid and the cellular target.
3Ease of manufacture
If conventional transfection methods are used, then production is simpler, but delivery efficiency decreases
Solution Approach 1:
The patent creates composite lipid-nucleic acid complexes where lipids are specifically designed to work synergistically with nucleic acids. The composite structure combines the ease of lipid synthesis with targeted delivery capabilities, achieving both production simplicity and high delivery efficiency through the emergent properties of the complex.
Solution Approach 2:
The patent optimizes multiple parameters of the lipid compositions including fatty acid chain length, saturation, headgroup composition, and charge density to maximize delivery efficiency. These parameter optimizations enable conventional non-viral methods to achieve viral-level efficacy while maintaining production simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the delivery of nucleic acids into cells, improving the efficiency and functionality of gene therapy applications by forming complexes that can penetrate cell membranes without the need for viral vectors, thereby overcoming existing delivery challenges.
Implementation Method 1
Elements (a) and (b) are typically non-covalently linked to form a complex
Implementation Method 2
a cell-penetrating mechanism
Data Source
AI summary
Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.